News

Cravatt is recognized for major technical advances in activity-based protein profiling, which is used to find potential new targets and drug candidates for cancer treatment.

A tiny genetic mutation to the virus that causes COVID-19 leads to a significant change in the virus’ ability to infect cells, according to new research from Hyeryun Choe, PhD, and Michael Farzan, PhD.

Scripps Research is collaborating with top computational scientists at Johns Hopkins University and UCLA.

On behalf of the institute, the leadership team at Scripps Research voices its recommitment to expanding diversity and inclusion across its campuses.

Analysis of data from 16 groups of COVID-19 patients suggest “silent” carriers may exacerbate efforts to stop spread of the disease

Scientists discovered a way to enhance the activity of an enzyme long suspected of playing a role in metabolism. In a study involving mice, the compound reversed signs of diabetes.

Response to essay published in Angewandte Chemie.

The drug, developed at Scripps Research, recently gained U.S. and European regulatory approval for the treatment of multiple sclerosis. It is also being studied for Crohn’s disease.

The news comes less than two months after the therapy gained approval from the U.S. Food and Drug Administration. Ozanimod is also in advanced clinical development for moderate-to-severe ulcerative colitis and Crohn’s disease.

In experiments on human 'mini-brains,' the drug preserved nerve connections that are lost to Alzheimer’s. The drug is also being evaluated for COVID-19, as it is known to inhibit viral activity.

How does general anesthesia cause loss of consciousness? Despite its 175-year-history of use by the U.S. medical system, science has been unable to definitively answer that question, until now.

Patapoutian, who made transformative discoveries about proteins that sense pressure, becomes the first Scripps Research scientist to win the Kavli Prize. 

Even though the coronaviruses that cause SARS and COVID-19 are closely related and infect cells the same way, they aren’t cross-protective in cell culture experiments.

The Skaggs Graduate School of Chemical and Biological Sciences awarded doctorates to 44 young scientists who comprise the 28th graduating class at Scripps Research. In lieu of the traditional annual commencement ceremony, a virtual celebration will be held in July.

A hallmark of cancer cells is that they lack contact inhibition, even when crowded. A new study from Kissil lab reveals a protein biologists thought they knew well, YAP, is playing an unexpected role in switching off that normal, healthy response, with input from many players.

Scripps Research, Florida Chemistry Professor Matthew Disney, PhD, has been honored with a prestigious Research Program Award from the National Institute of Neurological Disorders and Stroke (NINDS), to aid Disney’s development of treatments for incurable diseases such as Alzheimer’s, Parkinson’s, ALS and frontotemporal dementia.

The mechanism underlying Parkinson’s dyskinesia has been unknown, until now. An international collaboration led by Scripps Research, Florida has found a key cause, and with it, potentially, a new route to providing relief.

Patapoutian, a professor in Scripps Research’s Department of Neuroscience, has catapulted the scientific understanding of sensory transduction—the methods by which the body responds to sensory input from the eyes, tongue, nose and skin.

Clinical trials are assessing whether the drug can temper the immune system’s response to coronavirus in the lungs, preventing the dangerous inflammation seen in patients with severe disease.

Using some of the most powerful microscopes available to scientists today, structural biologists at Scripps Research have developed a method for examining the machinery of HIV in unprecedented detail.

Once a cancer patient’s tumors develop resistance to chemotherapy, the prognosis can be poor. However, inhibiting a key gene involved in multidrug resistance, MDR1, has not improved outcomes. A new study offers a reason, revealing unintended downstream effects on immune system cells.

An international research network centers around ReFRAME, the world’s leading collection of drugs known to be safe in humans.

In experiments, mice inoculated with virus-mimicking particles showed a stronger antibody response than when inoculated with hepatitis C proteins on their own.